title: HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
abstract: Recent evidence suggests that trastuzumab, a monoclonal antibody which targets HER2, in combination with chemotherapy is a therapeutic option in patients with HER2-positive gastric or gastroesophageal junction cancer. Widely accepted guidelines for HER2 testing in gastric and gastroesophageal junction cancer have not been established. The purpose of this study was to analyze the incidence and patterns of HER2 expression in gastric and gastroesophageal junction cancer using a tissue microarray approach, which closely simulates small biopsies routinely tested for HER2. One hundred sixty-nine patients, including 99 primary gastric adenocarcinomas and 70 primary gastroesophageal junction carcinomas were analyzed for HER2 overexpression by immunohistochemistry and HER2 gene amplification by fluorescence in situ hybridization using scoring schemes proposed by both American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) and the results of the recently published Trastuzumab for Gastric Cancer (ToGA) trial. In our analysis, 19 adenocarcinomas were HER2 positive, defined as either a HER2/CEP17 ratio >2.2 and/or a 3+ HER2 immunohistochemistry score with either the ASCO/CAP or ToGA scoring schemes. Of the 19 HER2-positive adenocarcinomas, 8 (42%) exhibited a characteristic strongly intense basolateral membranous staining pattern which would be interpreted as negative (1+) using the accepted ASCO/CAP scoring scheme for HER2 assessment in breast carcinoma, but were correctly labeled as 3+ positive using the proposed ToGA scoring scheme. Of the 19 HER2-positive adenocarcinomas, 8 (42%) demonstrated heterogeneous HER2 protein expression by immunohistochemistry. Twelve of 99 (12%) gastric carcinomas were positive for HER2. Of these, HER2 was more often identified in intestinal-type adenocarcinomas (10 of 52, 19%) compared with diffuse (2 of 34, 6%) adenocarcinoma. Seven of 70 (10%) gastroesophageal junction carcinomas were positive for HER2 of which all were intestinal type (7 of 58, 12%). HER2 status or primary tumor site did not correlate with patient survival. Gastric and gastroesophageal junction adenocarcinomas typically display a characteristic basolateral membranous pattern of HER2 expression which is often heterogeneous rendering routine evaluation of HER2 status on small tissue samples challenging.
authors: Department of Medicine/Oncology, Stanford University, Stanford, CA 94305, USA.
authors: Pamela L
authors: PL
authors: Kunz
authors: Amirkaveh
authors: A
authors: Mojtahed
authors: George A
authors: GA
authors: Fisher
authors: James M
authors: JM
authors: Ford
authors: Daniel T
authors: DT
authors: Chang
authors: Raymond R
authors: RR
authors: Balise
authors: Charles D
authors: CD
authors: Bangs
authors: Athena M
authors: AM
authors: Cherry
authors: Reetesh K
authors: RK
authors: Pai
references: Ann Surg Oncol. 2003 Apr;10(3):234-41
references: 12679307
references: Nat Med. 1998 Jul;4(7):844-7
references: 9662379
references: Cell Oncol. 2010;32(1-2):57-65
references: 20208134
references: Jpn J Clin Oncol. 2003 Apr;33(4):173-9
references: 12810831
references: World J Surg. 2009 Oct;33(10):2112-8
references: 19636613
references: Ann Surg Oncol. 2003 Oct;10(8):882-9
references: 14527906
references: Int J Surg Pathol. 2002 Oct;10(4):247-56
references: 12490974
references: N Engl J Med. 2001 Sep 6;345(10):725-30
references: 11547741
references: Hum Pathol. 2009 Jun;40(6):769-77
references: 19269014
references: J Clin Oncol. 2007 Jan 1;25(1):118-45
references: 17159189
references: Arch Pathol Lab Med. 2007;131(1):18-43
references: 19548375
references: J Clin Oncol. 2006 Nov 20;24(33):5201-6
references: 17114652
references: Int J Colorectal Dis. 2003 Mar;18(2):160-6
references: 12548420
references: Int J Cancer. 2002 Apr 20;98(6):833-7
references: 11948459
references: Lancet. 2010 Aug 28;376(9742):687-97
references: 20728210
references: Histopathology. 2008 Jun;52(7):797-805
references: 18422971
references: Oncol Rep. 2006 Jan;15(1):65-71
references: 16328035
references: Int J Biol Markers. 2007 Jan-Mar;22(1):12-8
references: 17393356
references: Hum Pathol. 2001 Apr;32(4):368-78
references: 11331953
references: Can J Gastroenterol. 2006 Apr;20(4):271-6
references: 16609756
references: Hum Pathol. 2001 Apr;32(4):379-88
references: 11331954
references: World J Gastroenterol. 2008 Jan 7;14(1):70-5
references: 18176964
references: J Clin Pathol. 2010 Sep;63(9):839-42
references: 20696687
references: Histopathology. 2001 Feb;38(2):96-104
references: 11207822
references: Int J Cancer. 2001 Oct 1;94(1):1-5
references: 11668471
references: Hum Pathol. 1988 Feb;19(2):166-78
references: 3343032
references: Am J Gastroenterol. 2008 Sep;103(9):2333-40; quiz 2341
references: 18671819
references: Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907
references: 20647400
references: Int J Oncol. 2003 Nov;23(5):1381-7
references: 14532980
references: Mod Pathol. 2007 Jan;20(1):120-9
references: 17143264
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: J Clin Oncol. 2000 Jun;18(11):2201-9
references: 10829039
references: N Engl J Med. 2006 Jul 6;355(1):11-20
references: 16822992
references: J Cancer Res Clin Oncol. 2009 Oct;135(10):1331-9
references: 19337752
references: Virchows Arch. 2010 Sep;457(3):299-307
references: 20665045
references: Genes Chromosomes Cancer. 1991 Jan;3(1):1-7
references: 2069905
references: Br J Cancer. 2009 Feb 10;100(3):487-93
references: 19156142
references: Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004064
references: 15846694
references: Ann Oncol. 2010 Oct;21(10):1999-2004
references: 20332133
references: Lab Invest. 1998 Mar;78(3):345-51
references: 9520947